Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161051 · ClinicalTrials.gov registry record
Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 287
- Enrollment target
NCT06161051 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 287 participants.
The verdict
NCT06161051 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 287 participants
- Enrollment target
Study Summary
This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation who received treatment with capmatinib, immunotherapy (IO), or chemotherapy (CT) in real-world practice settings. Data abstraction was performed by the participating physician.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2022-12-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06161051
The ClinicalTrials.gov registry entry for NCT06161051 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 287 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06161051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06161051 about?
NCT06161051 is a clinical study titled "Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States". This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation who received treatment with capmatinib, immunotherapy (IO), or chemotherapy (CT) in real-world practice settings. Data ab...
What is the current status of trial NCT06161051?
This trial is currently completed. The enrollment target is 287 participants. The study started on 2022-10-03. Estimated completion is 2022-12-07.
Who is sponsoring clinical trial NCT06161051?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.